Ridgecrest Wealth Partners’s AbbVie ABBV Stock Holding History

Ridgecrest Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.81M	Hold	8,338	–	–	1%	23
2025 Q4	$1.91M	Buy	8,338 +86	+1%	+$19.6K	1.03%	23
2025 Q3	$1.91M	Buy	8,252 +2	+0%	+$407	0.86%	25
2025 Q2	$1.53M	Sell	8,250 -3	-0%	-$558	0.81%	29
2025 Q1	$1.73M	Buy	8,253 +350	+4%	+$68K	0.91%	26
2024 Q4	$1.4M	Hold	7,903	–	–	0.76%	28
2024 Q3	$1.56M	Buy	7,903 +198	+3%	+$37K	0.81%	24
2024 Q2	$1.32M	Buy	7,705 +34	+0.4%	+$5.63K	0.8%	27
2024 Q1	$1.4M	Hold	7,671	–	–	0.83%	27
2023 Q4	$1.19M	Sell	7,671 -519	-6%	-$75.7K	0.79%	31
2023 Q3	$1.22M	Hold	8,190	–	–	0.86%	28
2023 Q2	$1.1M	Hold	8,190	–	–	0.73%	28
2023 Q1	$1.31M	Hold	8,190	–	–	0.93%	24
2022 Q4	$1.32M	Hold	8,190	–	–	1.01%	24
2022 Q3	$1.1M	Sell	8,190 -3,150	-28%	-$452K	0.9%	26
2022 Q2	$1.74M	Hold	11,340	–	–	1.26%	22
2022 Q1	$1.84M	Hold	11,340	–	–	1.17%	20
2021 Q4	$1.53M	Buy	11,340 +74	+0.7%	+$8.74K	0.75%	32
2021 Q3	$1.22M	Buy	11,266 +576	+5%	+$65.8K	0.66%	36
2021 Q2	$1.2M	Buy	10,690 +2,400	+29%	+$270K	0.75%	35
2021 Q1	$897K	Buy	+8,290	New	+$887K	0.86%	37

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ridgecrest Wealth Partners's ABBV Position: Q1 2026 in Review

Ridgecrest Wealth Partners held its AbbVie (ABBV) position steady in Q1 2026 at 8,338 shares worth $1.81M. The position accounts for 1% of the portfolio, ranked #23.

Ridgecrest Wealth Partners first reported a position in ABBV in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.91M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ridgecrest Wealth Partners held 8,338 shares of AbbVie worth $1.81M as of Q1 2026.
Ridgecrest Wealth Partners left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 1% of Ridgecrest Wealth Partners's portfolio in Q1 2026, its #23 holding.
Ridgecrest Wealth Partners first reported a position in AbbVie in Q1 2021 and has held it in 21 quarters since.
Ridgecrest Wealth Partners's AbbVie position peaked at $1.91M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ridgecrest Wealth Partners's 13F filing for Q1 2026, filed 22 Apr 2026.